When it comes to government approval, the burden of proof should fall upon merger opponents, not the businesses in question. More often than not, this isn’t the case. Take for instance, the pending Bayer-Monsanto deal. Some see the price tag of the deal (valued at $66 billion) and immediately become apprehensive. The price of the deal shouldn’t matter (unless you’re a shareholder); the contents of what the company does, should.
Read full story here.